Question for written answer E-005421/2021
to the Commission
Rule 138
Jean-Lin Lacapelle (ID), **Patryk Jaki** (ECR), **Aurélia Beigneux** (ID), **Herve Juvin** (ID), **Jean-Paul Garraud** (ID), **Julie Lechanteux** (ID), **Sylvia Limmer** (ID), **Jérôme Rivière** (ID), **Dominique Bilde** (ID), **Joachim Kuhs** (ID), **Gilles Lebreton** (ID), **Maximilian Krah** (ID), **Annika Bruna** (ID), **Filip De Man** (ID), **Hélène Laporte** (ID), **Gunnar Beck** (ID)

Subject: Irregularities in the Pfizer clinical trials

On 3 November 2021, the prestigious *British Medical Journal* published an explosive article on the conditions in which the Pfizer laboratory developed the Comirnaty vaccine in autumn 2020[1].

Several 'whistle-blowers' gave concurrent accounts of the problems with the vaccine clinical trials, including mislabelled laboratory specimens, vaccines not being stored at proper temperatures, unblinded patients and protocol deviations not being reported.

But even more seriously, patients were left unmonitored by clinical staff and some side effects were not recorded, compromising the results of the trial.

The Comirnaty vaccine has since been administered 430 million times in the EU.

In the light of these revelations, and bearing in mind that Pfizer has just concluded new trials on children aged 5-11:

1. Will the Commission investigate Pfizer's clinical trials and the real effects of the Comirnaty vaccine?

2. On the basis of the precautionary principle, will it suspend the conditional marketing authorisation granted to Pfizer?

3. On the basis of the principle of transparency, will it inform Europeans of the findings and keep them up to date with its investigation?

[1] https://www.bmj.com/content/375/bmj.n2635